September 26, 2018
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Full Approval to Afami-Cel for Advanced Synovial Sarcoma
2
Venetoclax/Ibrutinib Clears Resistance Mutations in BTK Inhibitor–Resistant CLL
3
Dose-Modified, Fixed-Duration Ibrutinib Plus Venetoclax Meets ORR End Point in Untreated CLL
4
Sigvotatug Vedotin Fails to Improve OS in Advanced, Pretreated Nonsquamous NSCLC
5